S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:OCUL

Ocular Therapeutix (OCUL) Stock Price, News & Analysis

$9.31
+0.11 (+1.20%)
(As of 03/27/2024 ET)
Today's Range
$9.13
$9.54
50-Day Range
$3.85
$10.93
52-Week Range
$2.00
$11.31
Volume
1.07 million shs
Average Volume
2.09 million shs
Market Capitalization
$1.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.80

Ocular Therapeutix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
80.5% Upside
$16.80 Price Target
Short Interest
Bearish
6.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
0.84mentions of Ocular Therapeutix in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$7 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.01 out of 5 stars

Medical Sector

214th out of 939 stocks

Pharmaceutical Preparations Industry

92nd out of 422 stocks

OCUL stock logo

About Ocular Therapeutix Stock (NASDAQ:OCUL)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Stock Price History

OCUL Stock News Headlines

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 5.8%
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Q4 2023 Clearside Biomedical Inc Earnings Call
Ocular Therapeutix (NASDAQ:OCUL) Upgraded at StockNews.com
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
OCUL Apr 2024 12.500 put
Decoding 6 Analyst Evaluations For Ocular Therapeutix
Ocular Therapeutix: Q4 Earnings Snapshot
Ocular Therapeutix earnings: here's what Wall Street expects
Earnings Outlook For Ocular Therapeutix
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/27/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OCUL
Employees
267
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.80
High Stock Price Target
$24.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+80.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-80,740,000.00
Net Margins
-138.15%
Pretax Margin
-138.15%

Debt

Sales & Book Value

Annual Sales
$58.44 million
Book Value
$0.79 per share

Miscellaneous

Free Float
140,453,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
1.32
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Antony MattessichMr. Antony Mattessich (Age 56)
    President, CEO & Director
    Comp: $1.05M
  • Mr. Donald Notman Jr.
    Chief Financial Officer
  • Dr. Jeffrey S. Heier M.D. (Age 63)
    Chief Scientific Officer
    Comp: $84.88k
  • Dr. Rabia Gurses Ozden M.D. (Age 56)
    Chief Medical Officer
    Comp: $621.39k
  • Dr. Pravin U. Dugel M.D. (Age 60)
    Executive Chairman
  • Dr. Peter K. Jarrett Ph.D. (Age 67)
    Chief Technology Officer
  • Mr. Philip C. Strassburger Esq. (Age 64)
    General Counsel
    Comp: $282.61k
  • Mr. William H. Ransone II
    Vice President of Global Sales & Marketing
  • Ms. Tracy Smith
    Vice President of Human Resources
  • Mr. Christopher G. White (Age 62)
    Chief Business Officer

OCUL Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price target for 2024?

5 analysts have issued 1 year target prices for Ocular Therapeutix's shares. Their OCUL share price targets range from $12.00 to $24.00. On average, they predict the company's stock price to reach $16.80 in the next twelve months. This suggests a possible upside of 80.5% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2024?

Ocular Therapeutix's stock was trading at $4.46 at the beginning of 2024. Since then, OCUL shares have increased by 108.7% and is now trading at $9.31.
View the best growth stocks for 2024 here
.

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our OCUL earnings forecast
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 321.12% and a negative net margin of 138.15%. During the same period last year, the business posted ($0.17) EPS.

What ETFs hold Ocular Therapeutix's stock?

ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a number of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (7.64%), Vanguard Group Inc. (6.44%), Vanguard Group Inc. (6.44%), Franklin Resources Inc. (5.67%), Deltec Asset Management LLC (3.08%) and Nuveen Asset Management LLC (1.27%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends
.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCUL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners